Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
RVV | CSE | CAD | Delayed | |
RVVTF | OTC Markets | USD | Delayed | |
RVV | CBOE Canada | CAD | Real-time |
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
Name | Age | Since | Title |
---|---|---|---|
William Jackson | 61 | 2014 | Independent Director |
Christian B. Scovenna | 48 | 2019 | Independent Director |
Joshua Jonathan Herman | - | 2019 | Independent Director |
Andrew Lindzon | - | 2019 | Independent Director |
Michael Frank | 60 | 2019 | Chairman & CEO |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review